Biomedical Advanced Research and Development Authority (BARDA)

Join us at the Vaccine Innovation Forum during JPM Week in San Francisco on January 13, 2025! This event will showcase breakthrough technologies in vaccine development and announce Concept Stage winners of the #PatchForwardPrize, a #ProjectNextGen competition to advance microneedle patch-based RNA vaccines for COVID-19, seasonal influenza, and pandemic influenza. Attendees also have a chance to connect with vaccine innovators, researchers, and investors to advance new technologies and develop the next generation of vaccine solutions to protect our nation’s health security. Advance registration is required. For more details, including information about the venue and what to expect from the agenda, check out the event page: https://lu.ma/tlruy9x2 We hope to see you there!

There's still time to submit your abstract to DRIVe & CBRN’s ReDIRECT program area of interest! This program supports the development of repurposed therapeutics to treat injuries caused by chemical threats like cyanide, respiratory depressants including opioids, nerve agents, chlorine, and sulfur mustard. Deadline to submit your abstract is March 31, 2025. Full details: https://ow.ly/ZebV50Uk7rl

Happy Holidays from BARDA! We wish you all peace, joy, health, and happiness as we enter this holiday season, and into the new year!

BARDA is partnering with Fred Hutch Cancer Center to support validation of an intracellular staining assay for testing of clinical samples from Project NextGen studies. This project will advance scientific knowledge of T-cell immune responses produced by next-generation vaccines to protect against emerging SARS-CoV-2 variants. The award was made under the Rapid Response Partnership Vehicle and is supported with funding from #ProjectNextGen. Learn more: https://ow.ly/L1RE50UwfG3

BARDA is accepting abstracts for our Influenza Vaccine Innovation program, under the EZ-BAA Area of Interest (AOI) #28. We’re seeking to develop novel influenza vaccines that can provide broader and longer-lasting protection against pandemic flu. This includes vaccines that can: ✔️ Provide protection against pandemic and seasonal viruses ✔️ Use oral, intranasal, or inhaled delivery routes ✔️ Extend the duration of protection beyond that provided by current influenza vaccines Learn more about our EZ-BAA AOI #28 and submit by January 20, 2025: https://ow.ly/CJXA50UwfAm

We’re hiring a Supervisory Public Affairs Specialist to lead public affairs and strategic communications for BARDA. In this role, you will: ✔️ Supervise a team of communications subject matter experts ✔️ Design communication strategies that support BARDA’s mission and work ✔️ Disseminate information to the news media, other government agencies, potential partners, trade associations, private organizations, advocacy groups, and other stakeholders ✔️ Prepare materials for responses to congressional inquires, correspondence, and hearing preparation This position is open to federal employees, veterans, and military spouses. Applications close 12/29, or once 100 submissions have been received. To learn more and apply: https://ow.ly/1cMI50Uv7ul

There's still time to submit your abstract to DRIVe & CBRN’s ReDIRECT program area of interest! This program supports the development of repurposed therapeutics to treat injuries caused by chemical threats like cyanide, respiratory depressants including opioids, nerve agents, chlorine, and sulfur mustard. Deadline to submit your abstract is March 31, 2025. Full details: https://ow.ly/ZebV50Uk7rl

Are you passionate about advancing our nation’s biodefense capabilities? Apply to join the National Biodefense Science Board #NBSB and help shape strategies to protect public health against emerging threats. This unique opportunity allows you to work with leading experts on challenges related to infectious diseases, biotechnology, and national health security. Applications close on January 11, 2025. Get the details: https://lnkd.in/dSnCbunX #Biodefense #PublicHealth #NBSB

Today is the last day to become a Decentralized Clinical Operations for Healthcare and Research (D-COHRe) partner and to submit your proposal to the Strategic Partnership Solicitation! DRIVe is seeking strategic partnerships to enhance clinical research innovation with decentralized care capabilities and to enhance preparedness. Submit by 12 p.m. ET today: https://ow.ly/2CyA50StbcO

We are partnering with Thrixen to develop a multiplex, rapid, point-of-care (PoC) diagnostic capable of distinguishing between orthoebolaviruses (Zaire and Sudan) and malaria. Under this contract, BARDA will fund the development of the diagnostic to detect orthoebolaviruses, while Thrixen will fund the development of the diagnostic to detect malaria. The Multiplex PoC Diagnostics Platform is designed to use fingerstick blood samples without the need for complex samples processing. The system will be portable and battery-operated, making it suitable for use in remote environments with limited resources. A common issue during Ebola outbreaks is that other endemic diseases, such as malaria, present similar symptoms in the early stages. Rapid identification and differential diagnosis at PoC settings can help healthcare providers make more informed decisions about patient management, initiate treatment earlier, improve patient outcomes, and help prevent the spread of disease. Learn more about this award: https://ow.ly/xTHs50Ul9gr